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A B S T R A C T
Background: More than half of non-small cell lung cancer (NSCLC) patients present with metastatic disease at
initial diagnosis with an estimated five-year survival rate of ~5%. Despite advances in understanding primary
lung cancer oncogenesis metastatic disease remains poorly characterized. Recent studies demonstrate important
roles of long non-coding RNAs (lncRNAs) in tumor physiology and as prognostic markers. Therefore, we present
the first transcriptome analysis to identify lncRNAs altered in metastatic lung adenocarcinoma leading to the
discovery and characterization of the lncRNA LCAL62 as a prognostic biomarker.
Patients and methods: RNA-Seq, microarray, nanoString expression, and clinical data from 1,116 LUAD patients
across six independent cohorts and 83 LUAD cell lines were used to discover and evaluate the survival association
of metastasis associated lncRNAs. Coexpression and gene set enrichment analyses were used to establish gene
regulatory networks and implicate metastasis associated lncRNAs in specific biological processes.
Results: Our integrative analysis discovered LCAL62 as the most down-regulated lncRNA in metastasis. Further
low LCAL62 expression promoted aggressive phenotypes and regulated genes associated with metastasis (such as
metastasis repressor FOXA2). Low LCAL62 expression corresponded to poor overall patient survival across five
independent lung adenocarcinoma cohorts (n ¼ 881) including our own nanoString validation cohort.
Conclusion: We discovered that LCAL62 was down-regulated in lung cancer progression to promote invasive
phenotypes, and lower expression was significantly associated with poor patient outcome and aggressive lung
adenocarcinoma.
1. Introduction
Non-small cell lung cancer (NSCLC) accounts for ~85% of all lung
cancers and is the leading cause of cancer-related deaths worldwide [1].
Greater than 50% of patients present with metastasis at initial diagnosis
[2]. Furthermore, most patients with early stage and locally advanced
NSCLC eventually recur with metastatic disease, despite undergoing
potentially curative therapies. The five-year survival rate for metastatic
disease is ~5% [1]. Current inadequacies for stratifying patients with
aggressive disease presents a strong rationale to systematically identify
biomarkers of aggressive lung cancer to improve patient diagnosis and
care.
To date lung cancer treatment and research have primarily focused on
the deregulation of protein-coding genes, thereby missing potentially
important non-coding RNAs. Long non-coding RNAs have emerged as a
biologically and clinically relevant class of transcripts contributing to
tumorigenesis [3, 4]. We recently conducted a first-of-its-kind ab initio
transcriptome assembly of publicly available RNA-Seq data from ~550
primary lung cancer patients to discover 111 lung cancer associated long
non-coding RNAs (LCALs) altered in lung cancer [5]. Just as this study
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established the lung cancer lncRNA landscape in primary tumors for
researchers to further explore potential mechanisms [6] and biomarker
utility [7, 8], a similar systematic approach in lung cancer metastasis
would improve our understanding of disease progression. Despite the
availability of multiple RNA-Seq data collections derived from primary
tumors [5], none of these cohorts include metastatic lung cancer speci-
mens. While previous technologies such as microarrays were designed
primarily to monitor protein-coding gene expression levels, some plat-
forms can be exploited to monitor the expression of a subset of lncRNAs
[9]. Therefore, our study leveraged RNA-Seq, microarray, and nano-
String expression platforms to identify lncRNAs associated with lung
cancer metastasis and their use as biomarkers for stratifying patients with
poor outcome to ultimately improve patient care.
Through our integrative analysis we discovered 281 lncRNAs differ-
entially expressed in lung adenocarcinoma (LUAD) metastasis. We found
that low expression of LCAL62 (aliases LINC00261, onco-lncRNA-17 and
DEANR1), the most down-regulated lncRNA in metastatic disease, pro-
moted aggressive phenotypes in vitro. Furthermore, we found and vali-
dated that low expression of LCAL62 was associated with poor overall
survival in LUAD patients from five independent cohorts totaling 881
patients. We also observed a strong coexpression between LCAL62 and
FOXA2, a known tumor and metastasis suppressor of lung cancer [10].
Taken together, LCAL62 could serve as a biomarker of aggressive disease
and patient outcome in LUAD.
2. Materials and methods
2.1. Datasets and patients
Six public gene expression datasets representing 5,320 tumor samples
(1,035 LUAD patients, 83 LUAD cell lines, and 4,121 other cancer pa-
tients) were used for the discovery of metastasis associated lncRNAs,
functional prediction, and survival analysis of LCAL62. An independent
cohort of 81 LUAD patients were enrolled at Washington University
School of Medicine in St. Louis, MO (WashU cohort). Primary tumor
specimens were evaluated for LCAL62 and FOXA2 expression using the
nanoString nCounter platform. Informed consent was obtained from all
patients and the protocol was approved by the Washington University
Institutional Review Board (IRB). Dataset details are provided in Table 1.
2.2. Bioinformatics analysis
Microarray probes were repurposed by realigning their sequences
against the transcripts to identify probes uniquely mapped to a lncRNA.
TCGA RNA-Seq pre-alignments and microarray pre-normalized probe
expression were used for subsequent analyses. Differential expression
analysis was performed using the negative binomial model for RNA-Seq
raw counts and the two-sample t-test for microarray data. Digital tran-
script counts from nanoString nCounter assays were normalized ac-
cording to nanoString nCounter data analysis manual. The Kaplan-Meier
product limit method and Cox proportional hazard model was used to
evaluate association between gene expression and patient overall sur-
vival. More details of the bioinformatics methods can be found in the
Supplementary Methods.
2.3. Experimental characterization
Experimental methods are detailed in the Supplemental Methods.
3. Results
3.1. Discovery of down-regulated lncRNA LCAL62 in metastatic lung
adenocarcinoma
To identify lncRNAs altered in metastatic LUAD we leveraged a
publicly available microarray gene expression dataset, referred to as the
‘Bittner cohort’ (GSE2109), that included 72 primary tumors and 10
unmatched metastatic tumors from brain (2), adrenal gland (3), cere-
bellar tissue (1), small bowel (1), soft tissue of the arm (1), and secondary
lung tumor (2). We identified 5,357 probe sets in the microarray plat-
forms that uniquely mapped to 4,443 lncRNA genes compiled from
multiple annotation sources (Supplementary Methods). Comparison of
primary and metastatic tumors from the Bittner cohort identified 281
lncRNA genes differentially expressed in metastasis including 235 up-
regulated and 49 down-regulated lncRNAs (Figure 1a). We found up-
regulated lncRNAs known to promote tumor proliferation and metas-
tasis in lung and other cancers such as H19 [11], BCAR4 [12], SNHG1
[13], and MIR17HG [14]. Our previous study, using three independent
RNA-Seq cohorts, characterized 111 lncRNAs dysregulated in non-small
cell lung cancer primary tumors compared to matched normal tissues,
termed LCALs, including 78 lncRNAs dysregulated in LUAD [5]. We
hypothesized that a subset of LCALs may be dysregulated in metastasis
compared to primary tumors. To select a candidate for subsequent
characterization we prioritized lncRNAs that are altered throughout lung
cancer progression by overlapping the metastasis-associated lncRNAs
with our previously identified primary-associated lncRNAs, LCALs. A
total of 43 LCALs were uniquely annotated with at least one probe set
from the Bittner cohort microarray. We discovered LCAL62 had the most
dramatic decreased expression in metastasis (Figure 1a,b). Additional
analysis confirmed that LCAL62was downregulated in bonemetastasis of
patient derived xenografts (Figure 1c). LCAL62 was also down-regulated
in primary tumors compared with normal tissues (Figure 1d).
Initial characterization of the TCGA LUAD cohort identified lower
LCAL62 expression in proximal-inflammatory and proximal-
Table 1. Summary of patient cohorts and cell line datasets used in this study.





Bittner GSE2109 LUAD 82 0 82 (72Pþ10M) Affymetrix HG U133 Plus 2.0
TCGA NA LUAD 298 220 353 (55N þ 298P) RNA-Seq [17]
Others 4121 Not evaluated 4585 (464N þ 4121P) RNA-Seq [17]
Schabath GSE72094 LUAD 442 374 442P Rosetta/Merck Human RSTA Custom
Affymetrix 2.0 microarray
[18]
Der GSE50081 LUAD 128 124 128P Affymetrix HG U133 Plus 2.0 [19]
Rousseaux GSE30219 LUAD 85 82 85P Affymetrix HG U133 Plus 2.0 [20]
WashU NA LUAD 81 81 81P nanoString nCounter
CCLE NA LUAD 83 0 83 cell lines RNA-Seq
Total all tissues 5237
Total LUAD tissue 1116 881
Total LUAD cell lines 83
Total all tissues & cell lines 5320
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Figure 1. Low expression of LCAL62 associates with metastasis and cancer aggressiveness. (a) Volcano plot of the lncRNAs in the metastasis versus primary tumor
comparison from the Bittner cohort. LCAL62 is the most down-regulated lncRNA in metastasis; (b) Expression of LCAL62 in patients (Bittner) and (c) patient derived
cell lines and xenografts (GSE76194, P - patient primary tumor derived cell lines; M - matched bone metastases developed in mouse xenograft model); (d) Expression
of LCAL62 in primary tumors (TCGA RNA-Seq) compared with normal tissues (N - normal, P - matched primary, UP - unmatched primary) and (e) grouped by
expression-based subtypes (PI: proximal-inflammatory/squamoid, PP: proximal-proliferative/magnoid, TRU: terminal respiratory unit/bronchioid); (f) Cancer related
gene sets enriched in LCAL62 GSEA analysis (top - enrichment plot of a representative metastatic gene set in melanoma negatively co-expressed with LCAL62, bottom -
network of enriched gene sets). Nodes represent gene sets that are significantly correlated (red) or anti-correlated (blue) with LCAL62 expression, grouped by manually
curated categories (dashed circles). Node size represents the number of genes in the corresponding gene set. Edge width represents the number of genes shared
between gene sets.
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proliferative expression-based subtypes (Figure 1e). To further investi-
gate the involvement of LCAL62 in tumor progression and metastasis,
we employed a ‘guilt-by-association’ approach that assumes a lncRNA is
likely involved in similar biological processes as coexpressing protein-
coding genes [15, 16]. We found that low LCAL62 expression was
correlated with genes up-regulated in tumor growth and proliferation,
tumor stage and metastasis, epithelial mesenchymal transition (EMT),
and drug resistance (Figure 1f; FDR adjusted p < 0.001).
To further demonstrate if the lack of LCAL62 promotes aggressive
disease, lung cancer cells were cultured with StemXVivo (R&D Systems)
to induce an epithelial to mesenchymal transition (EMT) as determined
by changes in E-cadherin and N-cadherin protein levels, hallmark events
of EMT (Figure 2a). EMT-induced A549 and HOP62 cells showed a
dramatic 80% decrease in LCAL62 expression compared to untreated
cells (Figure 2b). Further, silencing LCAL62 in A549 cells increased
cellular motility relative to control cells expressing LCAL62. After
knockdown of LCAL62, with two independent siRNAs, cells were seeded
on a transwell membrane in a modified Boyden Chamber assay. After 18
h there was a significant 49% and 57.5% increase (p< 0.02, p< 0.001) in
migrated cells with siRNA 1 and siRNA 2 (at least 80% decreased LCAL62
expression), respectively, compared to control transfected cells
(Figure 3a, b, c). In HOP62 cells, there was a 16.2% and 22.5% increase
(p < 0.001) in migrated cells with siRNA 1 and siRNA 2 (at least 80%
decreased LCAL62 expression) compared to control transfected cells
(Figure 3d, e, f). Further silencing LCAL62 in both cell lines increased
cellular invasion compared to LCAL62 expressing cells. There was a
17.3% (p < 0.02) and 7.6% (p < 0.001) increase in invaded cells with
siRNA 1 and siRNA 2 in A549 cells (Figure 4a, b, c) and a 27.7% and
23.8% (p < 0.001) increase in invaded cells with siRNA 1 and siRNA 2 in
HOP62 cells (Figure 4d, e, f). These data support the in silico predictions
of decreased LCAL62 expression promoting aggressive phenotypes in
LUAD.
3.2. Low LCAL62 expression is associated with poor overall survival
Our ‘guilt-by-association’ analysis revealed a striking enrichment of
gene signatures for lung cancer survival (Figure 5a) suggesting that lower
LCAL62 expression is associated with poor clinical outcome. Building
upon this, we evaluated the clinical significance of LCAL62 on patient
overall survival within the TCGA LUAD cohort (n ¼ 220, RNA-Seq) [17].
Most patients in TCGA LUAD cohort presented with early stage disease.
As expected, there was an association between stage and outcome (p <
0.001, Table 2). We performed survival analysis stratifying patients by
median LCAL62 expression and stage and found that decreased expres-
sion of LCAL62 was significantly associated with poor overall survival in
LUAD patients (p ¼ 0.04, HR ¼ 1.9; Figure 5b). The survival effect was
similar in early and late stages although 5% significance was not reached
in stage III/IV due to the small sample size.
3.3. Microarray data across three independent cohorts confirms LCAL62
correlation with patient outcome
We confirmed association of LCAL62 expression with patient outcome
by leveraging public microarray data from three independent LUAD co-
horts totaling 583 patients (Figure 6a, Table 1). These cohorts included
the Schabath cohort (n ¼ 374) [18], Der cohort (n ¼ 124) [19], and
Rousseaux cohort (n ¼ 85) [20] that leveraged two microarray platforms
(Table 1). The majority of patients in these cohorts presented with early
stage LUAD (Table 2). Low expression of LCAL62 was strongly and
consistently associated with poor overall survival in all three cohorts
(Schabath, p¼ 0.0003, HR¼ 1.7; Der, p¼ 0.026, HR¼ 1.9; Rousseaux, p
¼ 0.025, HR ¼ 2.0) (Figure 6a).
3.4. Orthogonal validation of LCAL62 correlation with patient outcome
using nanoString
In addition to publicly available microarray datasets, we further
validated the prognostic significance of LCAL62 in our independent
WashU cohort (n ¼ 81, stages I/II) using the nanoString nCounter plat-
form. We confirmed low expression of LCAL62 was associated with poor
overall survival in the WashU cohort (p ¼ 0.023, HR ¼ 1.9; Figure 6b).
When patients from all cohorts were combined a significant association
was observed between low LCAL62 expression and poor survival in both
early and late stages (p ¼ 3.3  109, HR ¼ 1.9, Figure 6c). Overall, our
analysis using three independent platforms (RNA-Seq, microarray, and
nanoString) across five independent cohorts (n ¼ 881) revealed a
consistent association of LCAL62 expression with overall survival.
3.5. LCAL62 association with FOXA2
To identify LCAL62 target genes, we performed a coexpression anal-
ysis on six independent LUAD gene expression datasets (Table 1). The
most highly coexpressed protein-coding gene with LCAL62 was FOXA2
(Forkhead Box A2), a gene encoding a transcription factor upstream of
LCAL62 (Figure 7a) that is known to repress tumor growth andmetastasis
in multiple cancers including lung cancer [10]. Spearman correlation
coefficient of expression between LCAL62 and FOXA2 ranged from 0.84
to 0.93 (Figure 7b). We further validated the strong correlation between
LCAL62 and FOXA2 expression using the nanoString platform in our
Figure 2. Low LCAL62 expression in metastatic cells. (a) Western blot of A549
(left) and HOP62 (right) protein lysates collected after 5-day treatment with
StemXVivo showing EMT hallmark proteins (E-cadherin and N-cadherin) altered
during epithelial to mesenchymal transition. (b) Inducing epithelial to mesen-
chymal transition in the presence of StemXVivo supplement decreased LCAL62
expression in A549 (left) and HOP62 (right) cell lines as measured by quanti-
tative RT-PCR (qRT-PCR); n of 2. Full non-adjusted images of the Western blots
in this figure are provided in Fig. S1.
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independent cohort (WashU cohort, Spearman correlation ¼ 0.80,
Figure 7b).
Since cis-regulation of nearby genes is a common mechanism of
lncRNA gene regulation [21] we investigated the relationship between
LCAL62 and FOXA2. After silencing LCAL62 (at least 90% knockdown)
with two independent siRNAs there was a 37.8% and 25.8% (p < 0.05),
respectively, decrease in FOXA2 expression in A549 cells (Figure 8a) and
a 26.9% and 34.1% (p < 0.0005), respectively, decrease in FOXA2
expression in HOP62 cells (Figure 8b). Interestingly, silencing FOXA2
also caused a decrease in LCAL62 expression (p < 0.0005; Figure 8a,b).
Moreover, silencing FOXA2 (with 80% knockdown) in our lung cancer
cell models increased cellular migration and invasion similarly to phe-
notypes observed in LCAL62-silenced cells (Figure 9). A previous study
found that LCAL62 positively regulated FOXA2 in endoderm differenti-
ation by recruiting the SMAD2/3 transcription factor to the FOXA2
promoter [22]. We hypothesized this regulatory mechanism would be
conserved in the lung which is endoderm derived. In lung cancer models,
we determined that LCAL62 bound to SMAD2/3with a 20-fold and 5-fold
enrichment in the A549 and HOP62 cell lines, respectively, as deter-
mined by RNA immunoprecipitation (RIP) (Figure 8c,d). Further, A549
cells with stably silenced LCAL62 showed decreased occupancy of
SMAD2/3 at the FOXA2 promoter (Figure 10). These data highlight that
LCAL62 may control transcription of FOXA2 through its interaction with
SMAD2/3.
In contrast to the tissue-specific expression profiles commonly
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Figure 3. Low expression of LCAL62 increases cellular migration in lung cancer cell lines. (a,b) A549 cells were seeded on a transwell and DAPI-stained cells
quantified; (c) qRT-PCR confirmed knockdown of LCAL62 in A549 using two independent siRNAs. *p < 0.02, **p < 0.001; n of 3. (d–f) Similar results for HOP62 cells.
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were altered in multiple cancers suggestive of their conserved oncogenic
roles across cancer types [5, 16]. In addition to LUAD, LCAL62 was
down-regulated in lung squamous cell carcinoma (LUSC) under the gene
alias onco-lncRNA-17 [5,16]. Therefore, we expanded our analysis to
incorporate 12 cancer types using 4,938 TCGA RNA-Seq samples and
found that the expression of LCAL62was also decreased in thyroid cancer
(THCA), kidney cancer (KICH), stomach cancer (STAD), and liver cancer
(LIHC) (Figure 7c). Furthermore, coexpression analysis revealed that
LCAL62 and FOXA2 were highly correlated (in both tumor and normal
tissues) across multiple cancer types with LCAL62 differential expression
(Figure 7d). LCAL62 and FOXA2 were the top correlated genes in LUAD,
LUSC, STAD, and THCA. These results suggest LCAL62 has a conserved
role regulating FOXA2 across cancers.
4. Discussion
Our comprehensive and systematic analysis of metastatic lung cancer
is the first to show previously characterized non-coding RNAs in other
cancers (i.e., BCAR4 and MIR17HG) [12, 14] are also up-regulated in
metastatic lung cancer. Our systematic approach also revealed additional
uncharacterized lncRNAs that could serve as the basis for subsequent
mechanistic studies dissecting the role of lncRNAs in lung cancer
metastasis. We prioritized LCAL62 since the lack of LCAL62 promoted
aggressive phenotypes, associated with metastasis gene signatures, and
correlated with patient outcome. We previously discovered LCAL62 as a
down-regulated lncRNA in primary lung tumors via large-scale RNA-Seq
analysis. While this current work was under review, several studies
showed LCAL62 association with prognosis and function in vivo [24, 25,
26, 27]. However, these studies evaluated limited numbers of patients
and utilized single transcriptomic platforms. Here we provide the most
comprehensive and systematic evaluation of LCAL62 expression and as-
sociation with prognosis in the largest compendium of patients to date (n
¼ 1,116) from six multi-institutional and independent cohorts. Notably,
low LCAL62 expression consistently correlated with patient outcome
across 881 LUAD patients from five independent cohorts. Further sup-























































































Control siRNA siRNA 1 siRNA 2
Figure 4. Low expression of LCAL62 increases cellular invasion in lung cancer cell lines. (a,b) A549 cells were seeded on a Matrigel-coated transwell and DAPI-stained
cells quantified. (c) qRT-PCR confirmed knockdown of LCAL62 in A549 using two independent siRNAs. *p < 0.02, **p < 0.001; n of 3; (d–f) Similar results for
HOP62 cells.
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expression correlated with overall survival using microarray, RNA-Seq,
and nanoString expression platforms. Within individual cohorts we
observed a stronger association within early stage compared with late
stage patients, however this may be due to the limited number of late
stage patients. However, despite having only 69 and 58 late stage pa-
tients in the Schabath and TCGA cohorts, respectively, we still observed
an association between low LCAL62 expression and poor overall survival.
When the late stage patients from all cohorts were combined, a signifi-
cant association of low LCAL62 and poor overall survival was observed
supporting that LCAL62 is associated with patient outcome independent
of stage. Additionally, we showed that LCAL62 was associated with
recurrence-free survival despite a limited number of patients (n ¼ 387,
44%) with recurrence-free follow-up (p ¼ 0.00045, HR ¼ 1.8, combined
cohort, Table 3).
Through computational prediction of LCAL62 function, we found
gene signatures supporting an association of LCAL62 with metastasis.
Our in vitro findings support our clinical observations by demonstrating
that initiating EMT in lung cancer models resulted in a dramatic decrease
in LCAL62 expression, and silencing LCAL62 expression resulted in
increased cellular motility and invasiveness. Our analysis also revealed
the consistent coexpression across 1,116 lung cancer patients between
LCAL62 and the protein-coding gene, FOXA2, which is implicated as a
metastasis suppressor in LUAD [10]. FOXA2 expression also had an as-
sociation (although not as strong as LCAL62) with overall survival (p ¼
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Figure 5. Discovery of the association of low LCAL62 expression with poor overall survival in TCGA cohort. (a) LCAL62 co-expressed with gene signature of lung
cancer survival; (b) Low expression of LCAL62 correlated with poor survival in TCGA LUAD cohort.
Table 2. Association of clinical variables with overall survival across cohorts.
Variable TCGA Schabath Der Rousseaux WashU
n HR* p n HR* p n HR* p n HR* p n HR* p
Age 0.83–2.14 0.24 0.87–2.17 0.17 0.77–2.73 0.25 1.1–3.8 0.02 0.7–1.9 0.57
<65 92 103 40 27 55
65 128 271 84 55 27
Gender 0.52–1.30 0.41 1.1–2.4 0.016 0.81–2.47 0.22 0.5–2.3 0.83 1.1–3.0 0.02
Male 97 164 64 64 37
Female 123 210 60 18 44
Stage 1.7–4.3 1.6E-6 1.9–4.4 1.6E-7 NA NA NA NA NA NA
I & II 162 305 124 80 81
III & IV 58 69 0 2
* 95% confidence interval.
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1.6  105, HR ¼ 1.6, combined cohort) and recurrence-free survival (p
¼ 0.031, HR ¼ 1.4, combined cohort, Table 3). The interplay between
LCAL62 and FOXA2 was experimentally validated by silencing LCAL62
and observing decreased expression of FOXA2. Additionally, we deter-
mined that LCAL62 bound to SMAD2/3 to regulate FOXA2 expression in
lung cancer, a relationship previously shown in definitive endoderm
[22]. In contrast to the up-regulation of LCAL62 during endoderm
differentiation, we observed a decrease in LCAL62 in metastatic samples
potentially corresponding to dedifferentiation. However, subsequent
mechanistic studies are necessary to determine how the loss of LCAL62
confers malignant phenotypes. We also believe this relationship extends
beyond lung cancer. Our pan-cancer analysis revealed consistent coex-
pression between LCAL62 and FOXA2 in multiple cancer types suggesting
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Figure 6. Orthogonal and independent validation of the association of low LCAL62 expression with poor overall survival. (a) Public microarray datasets; (b) WashU
nanoString cohort; (c) Combination of all cohorts including microarray, nanoString, and TCGA RNA-Seq. Kaplan-Meier curves for late stage (III/IV) are not generated
for Der, WashU (no late stage patients), and Rousseaux (only 2 late stage patients) cohorts.
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TCGA (n = 55)
cancer
normal
Figure 7. LCAL62 down-regulation and correlation with FOXA2 are conserved across cancer types. (a) UCSC Genome browser screenshot of the LCAL62 and FOXA2
region; (b) Correlation of expression of LCAL62 and FOXA2 in lung adenocarcinoma across cohorts (TCGA, CCLE - RNA-Seq; Schabath, Der, Rousseaux; Bittner -
microarray; WashU - nanoString); (c) Down-regulation of LCAL62 and (d) correlation with FOXA2 in other cancer types (TCGA RNA-Seq, top - tumor, bottom -
normal). Expression is measured by log2(FPKMþ1) in RNA-Seq data and log2 (probe intensity) in microarray data; N - normal, P - matched primary, UP - un-
matched primary.
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Figure 8. LCAL62 regulates FOXA2 expression in lung cancer cell
lines. qRT-PCR determined a decrease in FOXA2 expression upon
silencing of LCAL62 relative to a scrambled control siRNA and
normalized to the control housekeeping gene, RPL32 in (a) A549 and
(b) HOP62 cell lines. RNA immunoprecipitation (RIP) assay coupled to
qRT-PCR showed LCAL62 binding to SMAD2/3 relative to IgG control
in (c) A549 and (d) HOP62 cells. As a positive control, U1 was
enriched for its binding partner, SNRNP70, in RIP assay. *p < 0.05, **p
< 0.0005, n of 2.
Figure 9. Low expression of FOXA2 increases aggressive phenotypes in lung cancer models. Increased cellular migration and invasion in (a,c) A549 and (b,d) HOP62
cells. qRT-PCR confirmed knockdown of FOXA2 in (e) A549 and (f) HOP62 cells for assays. *p < 0.0005 **p < 0.00001, n of 3.
H.X. Dang et al. Heliyon 6 (2020) e03521
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in silico and in vitro results suggest that LCAL62 regulates FOXA2 to
potentially help suppress metastasis across cancer types.
Overall, the poor patient outcome in advanced LUAD highlights a
critical need for molecular biomarkers that can stratify patients with
aggressive disease to improve patient care. Through our integrative
analysis of metastatic lung cancer samples we have discovered that
LCAL62 is down-regulated in lung cancer progression, loss of LCAL62
expression increases invasive phenotypes, and LCAL62 can serve as a
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